Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1976 Jan;57(1):1–7. doi: 10.1172/JCI108249

Intrinsic mineralocorticoid agonist activity of some nonsteroidal anti-inflammatory drugs. A postulated mechanism for sodium retention.

D Feldman, C Couropmitree
PMCID: PMC436618  PMID: 173739

Abstract

Because some nonsteroidal anti-inflammatory drugs (NSAID) induce salt and water retention and exhibit other steroid-like actions, studies were performed to ascertain whether these drugs possess intrinsic mineralocorticoid agonist activity. In vitro competitive binding assays utilizing tissue from adrenalectomized rats demonstrated that some NSAID can displace [3H]-aldosterone from renal cytoplasmic mineralocorticoid receptors. Displacement potency for these sites was in the sequence: aldosterone greater than spironolactone greater than phenylbutazone (PBZ) greater than aspirin (ASA) greater than indomethacin (IDM). Concentration ratios required to obtain significant displacement of [3H]aldosterone were high but clearly within the therapeutic range for PBZ and ASA but not IDM. The analogues oxyphenbutazone (OBZ) and sodium salicylate (SS) were similar in binding activity to PBZ and ASA, respectively. Lineweaver-Burk analysis revealed that the inhibition of [3H]aldosterone binding was competitive in nature. In addition, PBZ was shown to prevent the nuclear binding of [3H]aldosterone. In vivo injection of PBZ and ASA resulted in competition for [3H]aldosterone renal binding comparable to the in vitro studies. Administration of PBZ and OBZ to adrenalectomized rats resulted in significant salt retention whereas ASA and SS did not differ significantly from controls. Salt retention elicited by PBZ and OBZ was inhibited by spironolactone, a competitive mineralocorticoid antagonist. These data suggest that, despite nonsteroidal structures, PBZ and OBZ induce salt retention via a receptor-mediated mineralocorticoid pathway analogous to aldosterone action.

Full text

PDF
1

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BRODIE B. B., LOWMAN E. W., BURNS J. J., LEE P. R., CHENKIN T., GOLDMAN A., WEINER M., STEELE J. M. Observations on the antirheumatic and physiologic effects of phenylbutazone (butazolidin) and some comparisons with cortisone. Am J Med. 1954 Feb;16(2):181–190. doi: 10.1016/0002-9343(54)90333-2. [DOI] [PubMed] [Google Scholar]
  2. BURNS J. J., ROSE R. K., CHENKIN T., GOLDMAN A., SCHULERT A., BRODIE B. B. The physiological disposition of phenylbutazone (butazolidin) in man and a method for its estimation in biological material. J Pharmacol Exp Ther. 1953 Nov;109(3):346–357. [PubMed] [Google Scholar]
  3. CHARNOCK J. S., OPIT L. J., HETZEL B. S. Electrolyte distribution in rats following salicylate. Metabolism. 1961 Nov;10:874–882. [PubMed] [Google Scholar]
  4. Domenjoz R. Synthetic anti-inflammatory drugs: concepts of their mode of action. Adv Pharmacol. 1966;4:143–217. doi: 10.1016/s1054-3589(08)60099-x. [DOI] [PubMed] [Google Scholar]
  5. Feldman D., Funder J. W., Edelman I. S. Subcellular mechanisms in the action of adrenal steroids. Am J Med. 1972 Nov;53(5):545–560. doi: 10.1016/0002-9343(72)90152-0. [DOI] [PubMed] [Google Scholar]
  6. Funder J. W., Feldman D., Edelman I. S. Glucocorticoid receptors in rat kidney: the binding of tritiated-dexamethasone. Endocrinology. 1973 Apr;92(4):1005–1013. doi: 10.1210/endo-92-4-1005. [DOI] [PubMed] [Google Scholar]
  7. Funder J. W., Feldman D., Edelman I. S. The roles of plasma binding and receptor specificity in the mineralocorticoid action of aldosterone. Endocrinology. 1973 Apr;92(4):994–1004. doi: 10.1210/endo-92-4-994. [DOI] [PubMed] [Google Scholar]
  8. Funder J. W., Feldman D., Highland E., Edelman I. S. Molecular modifications of anti-aldosterone compounds: effects on affinity of spirolactones for renal aldosterone receptors. Biochem Pharmacol. 1974 May 15;23(10):1493–1501. doi: 10.1016/0006-2952(74)90386-4. [DOI] [PubMed] [Google Scholar]
  9. GABRIEL J. B., KATZ H. M., REIMAN J., LUGER N. M. DCA-like effects of butazolidine in normal subjects and in a patient with Addison's disease. Metabolism. 1955 Mar;4(2):119–128. [PubMed] [Google Scholar]
  10. GREEN J., WILLIAMS P. O. Effect of butazolidine on the excretion of water and electrolytes. Lancet. 1953 Mar 21;1(6760):575–577. doi: 10.1016/s0140-6736(53)91698-5. [DOI] [PubMed] [Google Scholar]
  11. HETZEL B. S., CHARNOCK J. S., LANDER H. Metabolic effects of salicylate in man. Metabolism. 1959 May;8(3):205–213. [PubMed] [Google Scholar]
  12. HOLT L. P., HAWKINS C. F. INDOMETHACIN: STUDIES OF ABSORPTION AND OF THE USE OF INDOMETHACIN SUPPOSITORIES. Br Med J. 1965 May 22;1(5446):1354–1356. doi: 10.1136/bmj.1.5446.1354. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Hofmann L. M., Krupnick M. I., Garcia H. A. Interactions of spironolactone and hydrochlorothiazide with aspirin in the rat and dog. J Pharmacol Exp Ther. 1972 Jan;180(1):1–5. [PubMed] [Google Scholar]
  14. JOHNSON H. P., Jr, ENGLEMAN E. P., FORSHAM P. H., KRUPP M. A., GREEN T. W., GOLDFIEN A. Effects of phenylbutazone in gout. N Engl J Med. 1954 Apr 22;250(16):665–670. doi: 10.1056/NEJM195404222501601. [DOI] [PubMed] [Google Scholar]
  15. Korenman S. G. Comparative binding affinity of estrogens and its relation to estrogenic potency. Steroids. 1969 Feb;13(2):163–177. doi: 10.1016/0039-128x(69)90004-x. [DOI] [PubMed] [Google Scholar]
  16. Liao S., Howell D. K., Chang T. M. Action of a nonsteroidal antiandrogen, flutamide, on the receptor binding and nuclear retention of 5 alpha-dihydrotestosterone in rat ventral prostate. Endocrinology. 1974 Apr;94(4):1205–1209. doi: 10.1210/endo-94-4-1205. [DOI] [PubMed] [Google Scholar]
  17. Marver D., Stewart J., Funder J. W., Feldman D., Edelman I. S. Renal aldosterone receptors: studies with (3H)aldosterone and the anti-mineralocorticoid (3H)spirolactone (SC-26304). Proc Natl Acad Sci U S A. 1974 Apr;71(4):1431–1435. doi: 10.1073/pnas.71.4.1431. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Opelz G., Terasaki P. I., Hirata A. A. Suppression of lymphocyte transformation by aspirin. Lancet. 1973 Sep 1;2(7827):478–480. doi: 10.1016/s0140-6736(73)92073-4. [DOI] [PubMed] [Google Scholar]
  19. Paulus H. E., Whitehouse M. W. Nonsteroid anti-inflammatory agents. Annu Rev Pharmacol. 1973;13:107–125. doi: 10.1146/annurev.pa.13.040173.000543. [DOI] [PubMed] [Google Scholar]
  20. Quintanilla A., Kessler R. H. Direct effects of salicylate on renal function in the dog. J Clin Invest. 1973 Dec;52(12):3143–3153. doi: 10.1172/JCI107514. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Ramsay A. G., Elliott H. C. Effect of acetylsalicylic acid on ionic reabsorption in the renal tubule. Am J Physiol. 1967 Aug;213(2):323–327. doi: 10.1152/ajplegacy.1967.213.2.323. [DOI] [PubMed] [Google Scholar]
  22. Reinicke C. Influence of non-steroid anti=inflammatory drugs (NSAIDd) on hepatic tyrosine aminotransferase (TA) activity in rats in vitro and in vivo. Biochem Pharmacol. 1975 Jan 15;24(2):193–198. doi: 10.1016/0006-2952(75)90276-2. [DOI] [PubMed] [Google Scholar]
  23. Rousseau G. G., Baxter J. D., Tomkins G. M. Glucocorticoid receptors: relations between steroid binding and biological effects. J Mol Biol. 1972 Jun 14;67(1):99–115. doi: 10.1016/0022-2836(72)90389-0. [DOI] [PubMed] [Google Scholar]
  24. SEELY J. R., ELY R. S., DONE A. K., AINGER L. E., KELLEY V. C. Studies of 17-hydroxycorticosteroids. IX. The influence of therapy on adrenal cortical function in patients with rheumatic fever. J Pediatr. 1955 Oct;47(4):434–441. doi: 10.1016/s0022-3476(55)80054-6. [DOI] [PubMed] [Google Scholar]
  25. TRINDER P. Rapid determination of salicylate in biological fluids. Biochem J. 1954 Jun;57(2):301–303. doi: 10.1042/bj0570301. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Tweeddale M. G., Ogilvie R. I. Antagonism of spironolactone-induced natriuresis by aspirin in man. N Engl J Med. 1973 Jul 26;289(4):198–200. doi: 10.1056/NEJM197307262890408. [DOI] [PubMed] [Google Scholar]
  27. Vane J. R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971 Jun 23;231(25):232–235. doi: 10.1038/newbio231232a0. [DOI] [PubMed] [Google Scholar]
  28. Winter C. A., Risley E. A., Silber R. H. Antiinflammatory activity of indomethacin and plasma corticosterone in rats. J Pharmacol Exp Ther. 1968 Jul;162(1):196–201. [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES